Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Palandri F, Bartoletti D, Iurlo A, Bonifacio M, Abruzzese E, Caocci G, Elli EM, Auteri G, Tiribelli M, Polverelli N, Miglino M, Heidel FH, Tieghi A, Benevolo G, Beggiato E, Fava C, Cavazzini F, Pugliese N, Binotto G, Bosi C, Martino B, Crugnola M, Ottaviani E, Micucci G, Trawinska MM, Cuneo A, Bocchia M, Krampera M, Pane F, Lemoli RM, Cilloni D, Vianelli N, Cavo M, Palumbo GA, Breccia M.
Palandri F, et al. Among authors: ottaviani e.
Cancer. 2022 Jul 1;128(13):2449-2454. doi: 10.1002/cncr.34216. Epub 2022 Apr 1.
Cancer. 2022.
PMID: 35363892
Free PMC article.